• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Renalytix plc (Amendment)

    5/27/22 3:53:30 PM ET
    $RNLX
    Medical Specialities
    Health Care
    Get the next $RNLX alert in real time by email
    SC 13G/A 1 brhc10038265_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Act of 1934

    (Amendment No. 1)*

    RENALYTIX AI plc

    (Name of Issuer)

    ORDINARY SHARES
    (Including Ordinary Shares Underlying American Depository Shares)

    (Title of Class of Securities)

    75973T101 (American Depository Shares)

    (CUSIP Number)

    March 31, 2022

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐
    Rule 13d-1(b)
      ☐
    Rule 13d-1(c)
      ☒
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 75973T101 (American Depository Shares)
    13G/A
    1
    NAMES OF REPORTING PERSONS
     
     
    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (“ISMMS”)
    EIN 13-6171197
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    New York
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    10,161,375 (1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    10,161,375 (1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,161,375 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    13.6% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1)
    Includes 204,501 Ordinary Shares issuable upon exercise of vested options (“Options”). The voting and investment authority of the Ordinary Shares is vested in those persons who from time to time are the executive officers of ISMMS.
    (2)
    Ownership calculation based on 74,760,432 Ordinary Shares to be outstanding as of April 12, 2022, as reported by the Issuer in a press release dated April 8, 2022.

    Page 2 of 8

    CUSIP No. 75973T101 (American Depository Shares)
    13G/A
    1
    NAMES OF REPORTING PERSONS
     
     
    THE MOUNT SINAI HOSPITAL (“MSH”)
    13-1624096
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    New York
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    1,897,500 (1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    1,897,500 (1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,897,500 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.5% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1)
    MSH is the record and beneficial owner of 948,750 American Depository Shares (“ADS”), equivalent to a total of 1,897,500 Ordinary Shares. Each ADS represents the right to receive two Ordinary Shares of Issuer. The voting and investment authority of the ADS, and underlying Ordinary Shares, is vested in those persons who from time to time are the executive officers of MSH.
    (2)
    Ownership calculation based on 74,760,432 Ordinary Shares to be outstanding as of April 12, 2022, as reported by the Issuer in a press release dated April 8, 2022.

    Page 3 of 8

    CUSIP No. 75973T101 (American Depository Shares)
    13G/A
    1
    NAMES OF REPORTING PERSONS
     
     
    MOUNT SINAI HOSPITAL GROUP, INC. (“MSHG”)
    46-4242915
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    New York
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    (1)
    As the sole member of MSH, MSHG may be deemed to beneficially own the ADS, and Ordinary Shares underlying ADS, held by MSH. MSHG disclaims beneficial ownership of all such securities.

    Page 4 of 8

    CUSIP No. 75973T101 (American Depository Shares)
    13G/A
    1
    NAMES OF REPORTING PERSONS
     
     
    MOUNT SINAI HOSPITAL SYSTEM, INC. (“MSHS”)
    46-4248304
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    New York
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    (1)
    As the sole member of ISMMS, MSHS may be deemed to beneficially own the Ordinary Shares and Options, and Ordinary Shares underlying Options, held by ISMMS. As the sole member of MSHG, MSHS may be deemed to beneficially own the ADS, and Ordinary Shares underlying ADS, held by MSH. MSHS disclaims beneficial ownership of all such securities.

    Page 5 of 8

    Item1.(a)
    Name of Issuer:
     
    Renalytix AI plc

     
    (b)
    Address of Issuer’s Principal Executive Offices:

    Finsgate
    5-7 Cranwood Street
    London EC1V 9EE
    United Kingdom

    Item2. (a)
    Name of Persons Filing:

    Collectively the following Reporting Persons are referred to as the “Joint Filers”:
    Icahn School of Medicine at Mount Sinai (“ISMMS”)
    The Mount Sinai Hospital (“MSH”)
    Mount Sinai Hospitals Group, Inc. (“MSHG”), sole member of MSH
    Mount Sinai Hospital System (“MSHS”), sole member of each of ISMMS and MSHG

    The Joint Filers may be deemed to collectively own an aggregate of 12,058,875 ordinary shares (the “Aggregate Ordinary Shares”) of Issuer, including (i) Ordinary Shares owned of record by ISMMS, (ii) Ordinary Shares underlying Options beneficially owned by ISMMS, and (iii) Ordinary Shares underlying ADS owned of record by MSH. Each of MSHS and MSHG disclaims beneficial ownership of the Aggregate Ordinary Shares.

    Issuer’s ADSs trade on the NASDAQ Global Market and Ordinary Shares trade on AIM, a market operated by the London Stock Exchange.

     
    (b)
    Address of Principal Business Office or, if none, Residence:

    The address of the principal business office of each Reporting Person is:
    One Gustave L. Levy Place
    New York, NY 10029

     
    (c)
    Citizenship:

    See Item 4 of the cover pages for citizenship or place of organization of each Reporting Person.

     
    (d)
    Title of Class of Securities:

    Ordinary Shares (including Ordinary Shares underlying American Depositary Shares).

     
    (e)
    CUSIP Number:

    Only the America Depository Shares have a CUSIP Number, which is 75973T101.

    Item 3.
    If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
     
    (e)
    ☐
    An investment adviser in accordance with § 240.13d-l(b)(l)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with § 240.13d-l(b)(l)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with § 240.13d-l(b)(l)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
     
    (j)
    ☐
    A non-U.S. institution in accordance with § 240.13d-l(b)(l)(ii)(J);
     
    (k)
    ☐
    Group, in accordance with § 240.13d-l(b)(l)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-l(b)(l)(ii)(J), please specify the type of institution:

    Page 6 of 8

    Item 4.
    Ownership.

    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4 as set forth below:


    (a)
    Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.


    (b)
    Percent of class:

    See Row 11 of cover page for each Reporting Person.


    (c)
    Number of shares as to which the person has:


    (i)
    Sole power to vote or to direct the vote

    See Row 5 of cover page for each Reporting Person.


    (ii)
    Shared power to vote or to direct the vote

    See Row 6 of cover page for each Reporting Person.


    (iii)
    Sole power to dispose or to direct the disposition of

    See Row 7 of cover page for each Reporting Person.


    (iv)
    Shared power to dispose or to direct the disposition of

    See Row 8 of cover page for each Reporting Person.

    Item 5.
    Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following c.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Persons.

    See Item 2 above.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certification.

    Not applicable.

    Page 7 of 8

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

    Dated: May 26, 2022

    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
     

     
    By:
    /s/ Stephen Harvey
     
    Name:
    Stephen Harvey
     
    Title:
    Chief Financial Officer
     
         
    THE MOUNT SINAI HOSPITAL
     
       
    By:
    /s/ Stephen Harvey
     
    Name:
    Stephen Harvey
     
    Title:
    Chief Financial Officer
     
         
    MOUNT SINAI HEALTH SYSTEM, INC.
     
       
    By:
    /s/ Stephen Harvey
     
    Name:
    Stephen Harvey
     
    Title:
    Chief Financial Officer
     
         
    MOUNT SINAI HOSPITALS GROUP, INC.
     

     
    By:
    /s/ Stephen Harvey
     
    Name:
    Stephen Harvey
     
    Title:
    Chief Financial Officer
     

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001


    Page 8 of 8

    Get the next $RNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNLX

    DatePrice TargetRatingAnalyst
    1/18/2022$30.00Buy
    HC Wainwright & Co.
    1/4/2022$24.00Buy
    BTIG
    10/4/2021$28.00Buy
    Guggenheim
    7/2/2021$38.00Buy
    Berenberg
    More analyst ratings

    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commencement of trading on OTCQB in the United States

      LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., that effective with the market open today its ADSs are now trading on the OTCQB. The Directors have considered the benefits of the Nasdaq listing against the cost of maintaining the listing and have decided to downlist the ADSs from Nasdaq, and a

      10/8/24 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

      LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will in

      7/11/24 7:00:03 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

      LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Comp

      6/27/24 6:30:18 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

      LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran's primary responsibility will be leading the KidneyIntelX global sales effort. He is a senior executive with over 30 years of diversified general management, strategic planning, and marketing/sales experience in the diagnostics and pharmaceutical industries in domestic and international markets. Mr. Doran serv

      9/7/23 7:00:27 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

      LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP ("Deloitte") in 2020, where she was a senior partner and served as one of Deloitte's life sciences

      7/3/23 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

      PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc

      5/12/22 1:00:00 PM ET
      $AERC
      $NVCR
      $PODD
      $RNLX
      Environmental Services
      Utilities
      Medical/Dental Instruments
      Health Care

    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renalytix plc

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      10/2/24 8:05:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Renalytix plc (Amendment)

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      4/26/24 4:01:17 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Renalytix plc

      SC 13G - Renalytix plc (0001811115) (Subject)

      4/4/24 10:15:51 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Financials

    Live finance-specific insights

    See more
    • Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

      LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration ("FDA") De Novo authorized kidneyintelX.dkd, and release of new real

      5/15/24 7:00:14 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

      LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to joi

      5/9/24 7:00:12 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

      LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events. The Company made significant progress during the quarter in revenue generation, reimbursement coverage, the publication of real-world evidence

      2/15/24 7:00:32 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Interim Chief Financial Office Jung Joel R

      4 - Renalytix plc (0001811115) (Issuer)

      6/13/24 4:15:05 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Jung Joel R

      3 - Renalytix plc (0001811115) (Issuer)

      6/5/24 4:17:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Icahn School Of Medicine At Mount Sinai acquired $2,340,094 worth of Ordinary Shares (9,360,374 units at $0.25) (SEC Form 4)

      4 - Renalytix plc (0001811115) (Issuer)

      4/26/24 4:01:47 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Renalytix plc

      DEF 14A - Renalytix plc (0001811115) (Filer)

      10/11/24 4:36:26 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by Renalytix plc

      PRE 14A - Renalytix plc (0001811115) (Filer)

      10/1/24 5:14:50 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix plc filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Renalytix plc (0001811115) (Filer)

      10/1/24 5:12:55 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Renalytix with a new price target

      HC Wainwright & Co. initiated coverage of Renalytix with a rating of Buy and set a new price target of $30.00

      1/18/22 6:09:55 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • BTIG initiated coverage on Renalytix with a new price target

      BTIG initiated coverage of Renalytix with a rating of Buy and set a new price target of $24.00

      1/4/22 6:53:29 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Guggenheim initiated coverage on Renalytix with a new price target

      Guggenheim initiated coverage of Renalytix with a rating of Buy and set a new price target of $28.00

      10/4/21 8:16:45 AM ET
      $RNLX
      Medical Specialities
      Health Care